Addressing the vaping epidemic: Policy and clinical observations to facilitate cessation
Vaping has emerged as a significant public health concern, with the WHO estimating over 100 million users globally in 2025, including approximately 15 million adolescents. Misleading marketing and social media advertisements have perpetuated misperceptions about the health risks of vaping, driving uptake particularly among adolescents and young adults. This paper reviews the current evidence, regulatory landscape, and clinical guidance, highlighting that regulatory interventions alone are insufficient, as the heterogeneity of regulatory environments across countries limits the applicability of blanket recommendations. A multipronged approach encompassing expanded pharmacotherapy options is needed. While no standardized vaping cessation guidelines exist, several countries are extrapolating from smoking cessation frameworks and expediting pharmacotherapy approvals, recognizing the urgency of addressing this growing epidemic.

New Molecule

5 New

New Formulation

3 New

New Indication

2 New

Markings
Shape
Form
Color 1
Color 2

MIMS is a trusted, accurate and user-friendly medication information platform. Designed to empower both healthcare professionals and general public to support informed healthcare decisions, our leading drug directory provides clear, reliable information on prescription drugs, over-the-counter medications and other medical resources.

Frequently Asked Questions

Absolutely. Our database is continuously updated by medical editors and references authoritative sources, ensuring accuracy and credibility.

Yes. You can access MIMS.com on desktop or mobile, and we also offer an app for on-the-go use.

Use the search bar located at the top of the homepage and enter either the brand name or generic name of the drug.

Go to "Diseases" and use the search bar located at the top of the page and enter the name of the disease.

Go to "Medical News & Updates" to access latest news and medical updates in MIMS.com